| Nov 7 |
DBV Technologies’ stock slides as financial woes worsens
|
| Nov 7 |
DBV Technologies GAAP EPS of -$0.32 beats by $0.03
|
| Oct 23 |
Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway
|
| Oct 23 |
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
|
| Sep 23 |
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
|
| Aug 2 |
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
|
| Jul 31 |
DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript
|
| Jul 30 |
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
|
| Jul 30 |
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
|
| Jul 29 |
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
|
